类风湿关节炎患者减量生物疾病改善抗风湿药物的成本效用分析

数据集获取（Figshare）

• 源站标题：Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
• DOI：10.1371/journal.pone.0226754
• 发布日期：2020-01-02
• 文件数：6 个
• 文件总体积：136.74 KB
• 源站页面：https://plos.figshare.com/articles/dataset/Cost-utility_analysis_of_de-escalating_biological_disease-modifying_anti-rheumatic_drugs_in_patients_with_rheumatoid_arthritis/11495397

命令行下载

curl -L -o "pone.0226754.s001.docx" "https://ndownloader.figshare.com/files/20549994"
curl -L -o "pone.0226754.s002.docx" "https://ndownloader.figshare.com/files/20549997"
curl -L -o "pone.0226754.s003.R" "https://ndownloader.figshare.com/files/20550000"
curl -L -o "pone.0226754.s004.R" "https://ndownloader.figshare.com/files/20550003"
curl -L -o "pone.0226754.s005.R" "https://ndownloader.figshare.com/files/20550006"
curl -L -o "pone.0226754.s006.R" "https://ndownloader.figshare.com/files/20550009"

文件清单

• pone.0226754.s001.docx（21.87 KB）
• pone.0226754.s002.docx（30.51 KB）
• pone.0226754.s003.R（67.18 KB）
• pone.0226754.s004.R（5.05 KB）
• pone.0226754.s005.R（5.05 KB）
• pone.0226754.s006.R（7.08 KB）

文件总体积 136.74 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Objective
Recent guideline updates have suggested de-escalating DMARDs when patients with rheumatoid arthritis achieve remission or low disease activity. We aim to evaluate whether it is cost-effective to de-escalate the biological form of DMARDs (bDMARDs).
Methods
Using a Markov model, we performed a cost-utility analysis for RA patients on bDMARD treatment. We compared continuing treatment (standard care) to a tapering approach (i.e., an immediate 50% dose reduction), withdrawal (i.e., an immediate 100% dose reduction) and tapering followed by withdrawal of bDMARDs. The parametrization is based on a comprehensive literature review. Results were computed for 30 years with a cycle length of three months. We applied the payer’s perspective for Germany and conducted deterministic and probabilistic sensitivity analyses.
Results
Tapering or withdrawing bDMARD treatment resulted in ICERs of €526,254 (incr. costs -78,845, incr. QALYs -0.1498) or €216,879 (incr. costs -€121,691, incr. QALYs -0.5611) compared to standard care. Tapering followed by withdrawal resulted in a loss of 0.4354 QALYs and savings of €107,969 per patient, with an ICER of €247,987. Deterministic sensitivity analysis revealed that our results remained largely unaffected by parameter changes. Probabilistic sensitivity analysis suggests that tapering, withdrawal and tapering followed by withdrawal were dominant in 39.8%, 28.2% and 29.0% of 10,000 iterations.
Conclusion
Our findings suggest that de-escalating bDMARDs in patients with RA may result in high cost savings but also a decrease in quality of life compared to standard care. If decision makers choose to implement de-escalation in daily practice, our results suggest the tapering approach.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.1371/journal.pone.0226754（source: https://plos.figshare.com/articles/dataset/Cost-utility_analysis_of_de-escalating_biological_disease-modifying_anti-rheumatic_drugs_in_patients_with_rheumatoid_arthritis/11495397）。